Aura Biosciences raises $69.9M, bolsters $177M cash to fund bel-sar Phase 3 into H1 2027

Aura Biosciences, Inc. (NASDAQ: AURA) - What's happening inside

Short version: the company accelerated clinical and manufacturing work on its lead VDC candidate belzupacap sarotalocan (bel‑sar), funded that activity with a May 16, 2025 follow‑on offering, and materially increased its cash and equity base - while R&D spend and net losses rose and the business remains single‑asset and cash‑burn dependent.

Key facts & statistics (as reported, unaudited, amounts in thousands unless noted)
- Cash and cash equivalents: $107,367 (June 30, 2025).
- Marketable securities: $69,944 (June 30, 2025).
- Combined cash, cash equivalents and marketable securities: ~$177.3 million (company disclosure).
- Total assets: $204,397; Total liabilities: $29,768; Total stockholders' equity: $174,629 (June 30, 2025).
- Shares issued and outstanding: 62,071,050 (June 30, 2025).
- 2025 Follow‑On Offering (May 16, 2025): issued 11,735,565 common shares, pre‑funded warrants for up to 3,571,435 shares and warrants for 3,826,750 shares; net proceeds ≈ $69.9 million.
- Net loss - three months ended June 30, 2025: $(27,019). Six months ended June 30, 2025: $(54,502).
- Net loss per share - three months: $(0.47); six months: $(1.01).
- Operating expenses (three months): Total $28,613 - R&D $22,882; G&A $5,731.
- Operating expenses (six months): Total $57,648 - R&D $46,225; G&A $11,423.
- R&D split (six months): Clinical trials $16,703; Manufacturing development $8,115; Personnel/overhead $20,723.
- Accumulated deficit: $(428,729).
- Net cash used in operating activities (six months): $(44,129).
- Net cash provided by investing activities (six months): $49,790 (maturities of marketable securities $60,000).
- Net cash provided by financing activities (six months): $70,025 (primarily follow‑on offering proceeds).
- Management liquidity guidance: existing cash and marketable securities expected to fund operations into the first half of 2027 (company estimate).

Positive aspects (income statement and corporate)
- Strong recent financing: ~ $69.9M net from the May 2025 follow‑on improved the balance sheet and extended runway into H1 2027.
- Cash + marketable securities of ~$177.3M provides a multi‑quarter funding cushion while Phase 3 and other clinical programs progress.
- Clinical progress: bel‑sar is in a global Phase 3 CoMpass trial (company expects enrollment possibly complete by end of 2025) and the company reported positive Phase 2 and Phase 1 NMIBC data supporting continued development and program expansion.
- Investing activity converted shorter‑term securities to cash (maturities), helping liquidity for near‑term operations.
- No revenue pressure (typical for clinical‑stage biotech) but interest income still contributed to "other income" ($3,271 six months, though down vs. prior year).

Negative / cautionary aspects (income statement and business)
- Rapidly rising R&D spend: R&D rose to $46,225 for six months (up $12,293 vs. prior year period). That increase drove larger operating losses.
- Bigger losses and dilution: six‑month net loss increased to $(54,502) (vs. $(40,043) prior year). Share count rose from ~50M to 62M - dilution from the offering and equity compensation.
- Cash burn remains significant: net cash used in operating activities was $(44,129) for six months, and the company will likely need additional funding before commercialization (management acknowledges more capital will be required to fund bel‑sar through approval).
- Single‑asset concentration: the company's value and near‑term prospects are heavily dependent on bel‑sar's clinical and regulatory success - high program risk.
- Manufacturing and third‑party reliance: increased manufacturing development costs and reliance on CDMOs introduce execution and supply risks that could affect costs and timelines.
- Accumulated deficit is large at $(428,729); no product revenue to offset R&D and G&A yet.

Operational signals inside the company
- Ramping clinical & CMC activity: higher clinical trial and manufacturing development spend confirms shift to late‑stage execution and preparation for potential commercial scale‑up.
- Hiring and retention: stock‑based compensation expense $7,347 (six months); unrecognized stock comp obligations for options $16.7M and RSUs $19.5M indicate continued people investments.
- Balance sheet moves: reallocation of marketable securities (maturities and purchases) and use of equity financing to shore up liquidity.
- Lease commitments and facility expansion: ongoing capital and rent commitments (operating lease liabilities net $14,916 long term; total operating lease payments future $26,020). This aligns with lab/office build‑out and scale requirements.

Bottom line - concise takeaways
- Aura (NASDAQ: AURA) has materially improved near‑term liquidity via the May 2025 follow‑on and now carries ~ $177M in cash and securities with runway guidance into H1 2027.
- The company is deploying that capital into an aggressive clinical and CMC ramp for bel‑sar (Phase 3 + other indications), which is why R&D expense and operating losses increased materially in H1 2025.
- Key risks remain: high cash burn, single‑asset dependency, dilution from equity financings, third‑party manufacturing and clinical execution risk, and no product revenue today.
- Investors should watch: progress/newsflow from the Phase 3 CoMpass trial, manufacturing comparability/scale‑up milestones, cash‑burn trajectory vs. guidance, and any additional financing or partnership activity.

If you want, I can convert key financial lines into a one‑page dashboard (income, cash flow, balance sheet highlights) or pull the specific Phase 3 and NMIBC milestones and anticipated timelines into a short milestone calendar.